Theranos Investors: The Billionaires, Generals, and Statesmen Who Got Fooled by a Turtleneck

In 2014, Theranos was valued at $9 billion. Its founder, Elizabeth Holmes, was on the cover of Fortune, Forbes, and Inc. She was hailed as the next Steve Jobs. Her board of directors included two former Secretaries of State, a former Secretary of Defense, a four-star Marine general, and a former U.S. Senator. Collectively, investors had poured approximately $945 million into the company. The technology — a revolutionary blood-testing device that could run hundreds of tests from a single drop of blood — was going to save lives, reduce healthcare costs, and democratize diagnostics for billions of people.

There was just one problem: it didn’t work. The technology never worked. And nearly a billion dollars went up in smoke because some of the wealthiest and most powerful people in America wrote enormous checks based on a handshake, a turtleneck, and a story that was too good to question.

This isn’t the Elizabeth Holmes story. That story has been told. This is the story of the people who believed her — the investors, board members, and power brokers who handed over their money, their reputations, and their credibility to a 19-year-old Stanford dropout. It’s a story about how intelligence, wealth, and experience provide zero protection against a well-constructed narrative.

---

💰 Chapter 1: The Money

Let’s start with the checks, because the numbers are staggering.

The single largest individual investor in Theranos was the Walton family — heirs to the Walmart fortune. They invested approximately $150 million through their family office. At the time, the Waltons were collectively worth over $150 billion. A $150 million investment was a rounding error on their balance sheet. But it was still $150 million dollars committed to a company whose core technology had never been independently validated.

Rupert Murdoch, the media mogul who controlled Fox News, The Wall Street Journal, and a global newspaper empire, invested $125 million. Murdoch — a man who had spent 60 years navigating the most complex media landscape on Earth, who had survived phone-hacking scandals, hostile regulators, and four divorces — wrote a check for $125 million based on a series of private meetings with Holmes.

Betsy DeVos, whose family fortune derived from Amway and who would later serve as U.S. Secretary of Education, invested approximately $100 million. The Cox family — heirs to Cox Enterprises, which owns Cox Communications and the Atlanta Journal-Constitution — put in roughly $100 million. Other investors included Mexican billionaire Carlos Slim (through a small stake), South African retail magnate Christo Wiese, hedge fund titan Robert Kraft, and the family offices of some of America’s wealthiest dynasties.

In total, approximately $945 million was invested in Theranos across multiple funding rounds. The company’s peak valuation of $9 billion made Holmes, who owned roughly 50% of the shares, worth $4.5 billion on paper — the youngest self-made female billionaire in history.

Every single dollar of that investment was eventually written down to zero.

---

🎭 Chapter 2: The Board

If the investor list was impressive, the board of directors was otherworldly.

George Shultz — former Secretary of State under Ronald Reagan, former Secretary of the Treasury under Richard Nixon, former president of Bechtel Corporation. He joined the Theranos board in 2011, when he was 91 years old. Shultz was so captivated by Holmes and her mission that he introduced her to virtually every powerful person in his extensive network.

Henry Kissinger — former Secretary of State, Nobel Peace Prize laureate, and arguably the most influential foreign policy strategist of the 20th century. He joined the board in 2013 at age 90.

William Perry — former Secretary of Defense under Bill Clinton, a Stanford professor and a genuine expert in technology and defense systems. Jim Mattis — a four-star Marine general who would later serve as Secretary of Defense under Donald Trump. Sam Nunn — a former U.S. Senator from Georgia and one of the most respected figures in defense policy. Gary Roughead — a retired four-star admiral and former Chief of Naval Operations.

The board was a murderer’s row of establishment power. And not a single member had expertise in biomedical technology, clinical diagnostics, or the regulatory pathways governing blood-testing devices.

This was the first red flag — visible in retrospect and invisible at the time. Holmes had constructed a board optimized for influence, not oversight. The board members could open doors at the Pentagon, the State Department, and the halls of Congress. What they couldn’t do was evaluate whether the Edison blood-testing device actually worked. And they never thought to ask anyone who could.

---

🧪 Chapter 3: What Wasn’t Working

The core promise of Theranos was simple and electrifying: a small, proprietary device called the Edison could run over 200 blood tests from a single finger prick — a few drops of blood from a fingertip, instead of the tubes of venous blood required by traditional testing.

The problem was that the Edison couldn’t do any of that.

According to trial testimony and John Carreyrou’s reporting in The Wall Street Journal, the Edison device could perform — at best — a handful of simple tests with unreliable accuracy. For the vast majority of the tests Theranos advertised, the company was secretly running patient samples on commercially available machines made by Siemens and other established manufacturers. They were diluting the tiny finger-prick samples to create enough volume for the traditional machines — a process that introduced significant error rates.

Theranos knew this. Internal quality control data showed failure rates that would have been disqualifying at any legitimate lab. Employees who raised concerns were silenced, threatened, or fired. The company’s president and Holmes’s boyfriend, Ramesh “Sunny” Balwani, ran the lab with an iron fist, reportedly screaming at employees who questioned the results.

But the investors didn’t know. They were never given access to the internal quality control data. They were never allowed to independently verify the technology. Holmes maintained that the technology was a trade secret — too sensitive to share, even with the people funding it.

And the investors accepted this. They accepted it because of who else was in the room.

---

🤝 Chapter 4: The Social Proof Machine

Here is the mechanism that made the fraud possible: social proof.

Social proof is the psychological phenomenon where people determine the correct course of action by looking at what other people are doing. It’s one of the most powerful cognitive shortcuts in human behavior. And in the Theranos case, it was weaponized.

Consider the calculus facing a potential Theranos investor in 2014. You’re a wealthy individual. You get a meeting with Elizabeth Holmes. She tells you about a revolutionary blood-testing technology. You’re not a scientist. You can’t evaluate the claims independently. So you look for signals.

Who’s on the board? George Shultz. Henry Kissinger. Jim Mattis. William Perry. These aren’t fools. These are some of the most accomplished, intelligent people in American public life. If they believe in this company, there must be something there.

Who else has invested? The Waltons. Rupert Murdoch. Betsy DeVos. These are people with teams of analysts, advisors, and due diligence professionals. If they’ve invested hundreds of millions, surely they’ve done the homework.

What does the press say? Forbes put Holmes on the cover. Fortune called her “the next Steve Jobs.” The New Yorker profiled her. If the media has validated the story, questioning it feels contrarian to the point of paranoia.

Each new investor became evidence for the next investor. Each new board member became validation for the next board member. The social proof compounded like interest, creating a feedback loop where everyone was relying on everyone else’s judgment — and no one was relying on the actual data.

This is the anatomy of a con. The con artist doesn’t need to fool everyone. She just needs to fool the first few credible people, and then their credibility does the rest of the work.

---

👴 Chapter 5: The Shultz Tragedy

The most heartbreaking story within the Theranos debacle belongs to the Shultz family.

George Shultz, the former Secretary of State, was one of Theranos’s most passionate advocates. He believed in Holmes. He believed in the mission. He used his vast network to introduce her to investors, government officials, and military leaders. His imprimatur was one of the single most valuable assets Theranos possessed.

In 2013, George Shultz’s grandson, Tyler Shultz, graduated from Stanford with a degree in biology and went to work at Theranos. He was excited. His grandfather’s enthusiasm was infectious, and the idea of revolutionizing blood testing appealed to his scientific idealism.

Within months, Tyler realized something was deeply wrong. The test results were unreliable. The quality control processes were inadequate. The company was, in his assessment, running fraudulent tests on real patients. He raised his concerns internally to Sunny Balwani, who dismissed them. He told his grandfather.

George Shultz didn’t believe him.

According to Tyler’s testimony and later interviews, his grandfather chose to believe Holmes over his own grandson. George Shultz was 93 years old. He had staked his reputation on Theranos. Accepting that it was a fraud meant accepting that he had been deceived — that his judgment, the judgment of a man who had advised presidents and negotiated with the Soviet Union, had failed catastrophically.

Tyler went to regulators. He contacted the New York State Department of Health. He became one of John Carreyrou’s key sources. Theranos’s lawyers — from the powerhouse firm Boies Schiller — pursued him aggressively, hiring private investigators to follow him and sending threatening legal letters.

George Shultz eventually came around. In February 2021, he died at age 100. Before his death, he had publicly acknowledged that Tyler was right and that he himself had been wrong. It was a quiet, painful reconciliation between a grandfather who had been conned and a grandson who had tried to save him from it.

---

📰 Chapter 6: The Unraveling

On October 16, 2015, John Carreyrou published the first of a series of articles in The Wall Street Journal revealing that Theranos was using its proprietary Edison device for only a small fraction of its tests and was running the rest on conventional machines. The articles cited anonymous sources, internal documents, and clinical data that contradicted virtually everything Theranos had told investors and the public.

Holmes fought back. She appeared on CNBC, on Jim Cramer’s Mad Money, on the TODAY show. She denied everything. She called Carreyrou’s reporting a hit job. She invoked her mission of saving lives. She wore the black turtleneck.

Rupert Murdoch — who owned The Wall Street Journal — reportedly asked Holmes about the stories during a private meeting. Holmes urged him to kill the investigation. Murdoch, to his credit, refused. He told Holmes that he didn’t interfere with WSJ’s journalism. It was one of the most expensive editorial decisions in media history: Murdoch let his own newspaper publish stories that would destroy his $125 million investment.

The dam broke quickly after that. The Centers for Medicare & Medicaid Services (CMS) inspected Theranos’s Newark, California lab in late 2015 and found deficiencies so severe that the agency determined the lab posed “immediate jeopardy to patient health and safety.” Theranos was banned from operating its blood-testing lab for two years. Walgreens, which had partnered with Theranos to offer in-store blood testing, terminated its partnership and sued for $140 million.

In March 2018, the SEC charged Holmes and Balwani with “massive fraud.” Holmes settled without admitting wrongdoing and agreed to pay a $500,000 fine and give up voting control of the company. In September 2018, Theranos officially dissolved.

---

⚖️ Chapter 7: The Trial and the Reckoning

In January 2022, Elizabeth Holmes was found guilty of four counts of federal wire fraud — specifically, defrauding investors. She was acquitted of charges related to defrauding patients. In November 2022, she was sentenced to 11 years and 3 months in prison. She reported to a federal prison in Bryan, Texas, on May 30, 2023.

Ramesh Balwani was convicted on all 12 counts and sentenced to nearly 13 years in prison.

But the investors never got their money back. The $945 million was gone — spent on salaries, office space, equipment, legal fees, and the elaborate theatrical production of a company that didn’t have a working product.

The financial losses, while enormous in absolute terms, were proportionally small for most of the investors involved. Rupert Murdoch’s $125 million was roughly 1% of his net worth. The Walton family’s $150 million was approximately 0.1% of their fortune. For billionaire investors, Theranos was an embarrassment, not a catastrophe.

But the reputational damage was real. These were people who prided themselves on judgment — on being smarter, savvier, and more perceptive than ordinary investors. The Theranos debacle proved that wealth and status don’t protect against fraud. If anything, they make you more vulnerable, because they create the social distance that prevents you from asking basic questions.

---

📋 Chapter 8: The Autopsy

What went wrong? How did nearly a billion dollars flow into a company that couldn’t do what it claimed?

Due diligence failure. The most basic explanation is that the investors didn’t do their homework. They didn’t demand audited clinical trial data. They didn’t hire independent biomedical consultants to evaluate the Edison device. They didn’t insist on third-party verification of Theranos’s test accuracy. In normal venture capital, this level of due diligence is standard. For Theranos, it was skipped — partly because of social proof, partly because Holmes actively prevented it by claiming trade secret protections.

Board composition failure. A board of directors is supposed to provide oversight. Theranos’s board was constructed to provide access. Not a single board member had the technical expertise to evaluate a diagnostic blood-testing device. The board could open doors in Washington but couldn’t ask the right questions in the lab.

Regulatory gap. Laboratory-developed tests (LDTs), which is how Theranos classified its technology, were subject to far less FDA scrutiny than commercial diagnostic devices. Theranos exploited this regulatory gray zone for years, operating its tests in a clinical setting without the rigorous review that a standard medical device would require.

Narrative over evidence. Holmes was a masterful storyteller. She pitched a world where anyone could get a comprehensive blood test from a finger prick at their local pharmacy. The story was emotionally compelling, socially important, and technologically plausible (to non-experts). Investors bought the story. They never demanded the evidence.

The Theranos investor debacle is not primarily a story about a charismatic fraudster. It’s a story about a system — Silicon Valley’s ecosystem of wealth, power, and social proof — that was designed to fund ambitious ideas quickly and was therefore structurally vulnerable to ambitious lies.

The investors who got burned weren’t stupid. They were operating in an environment where speed, conviction, and social signals mattered more than independent verification. In that environment, Theranos was inevitable. If Holmes hadn’t built it, someone else would have exploited the same blind spots.

The lesson isn’t “be smarter.” The lesson is: when everyone in the room is relying on everyone else’s judgment, nobody is actually judging. And that’s when the music stops.